Used in targeted cancer therapies due to its ability to act as a DNA alkylating agent. The compound’s structure allows it to cross cell membranes efficiently and bind selectively to tumor cell DNA, causing strand breaks and inhibiting replication. It is particularly explored in prodrug designs for chemotherapy, where it remains inactive until triggered by specific tumor microenvironment conditions such as low pH or elevated enzyme levels. Its dual chloroethyl groups enhance cross-linking efficiency, increasing cytotoxic effects on rapidly dividing cells. Research focuses on conjugating this molecule to monoclonal antibodies or ligands for improved tumor targeting and reduced systemic toxicity.